Pharmacotherapy for overactive bladder: minimally invasive treatment – botulinum toxins

Bibliography

• Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist 2008;12:289-98
   Google Scholar
• Apostolidis A, Dasgupta P, Denys P, Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus panel report. Eur Urol 2009;55:100-20
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Panicker JN, Drake M, A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 2009;85:552-9
   PubMed Web of Science ®Google Scholar
• Stohrer M, Blok B, Castro-Diaz D, EAU Guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81-8
   PubMed Web of Science ®Google Scholar
• Wyndaele JJC, Kovindha A, Madersbacher H, Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors, Incontinence. Health Publication Ltd, Paris; 2009. p. 793-960
   Google Scholar
• NICE. Clinical Guideline 40. Urinary Incontinence: the management of Urinary Incontinence in women. National Institute for Health and Clinical Excellence, London; 2006
   Google Scholar
• Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50
   PubMed Web of Science ®Google Scholar
• Haferkamp A, Schurch B, Reitz A, Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004;46:784-91
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Popat R, Yiangou Y, Decreased sensory receptors P2X3 And TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-83
   PubMed Web of Science ®Google Scholar
• Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(Suppl 1):S16-24
   PubMed Web of Science ®Google Scholar
• Coelho A, Dinis P, Pinto R, Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2010;57:884-90
   Google Scholar
• Smith CP, Franks ME, McNeil BK, Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003;169:1896-900
   PubMed Web of Science ®Google Scholar
• Howles S, Curry J, McKay I, Lack of effectiveness of botulinum toxin on isolated detrusor strips and whole bladders from small anumals in vitro. BJU Int 2009;104:1524-9; discussion 1529-30
   Google Scholar
• Schulte-Baukloh H, Knispel HH. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005;95:454
   PubMedGoogle Scholar
• Mehnert U, Boy S, Schmid M, A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 2009;27:397-403
   PubMedGoogle Scholar
• Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004;279:25665-72
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Di Stasi SM, Nardicchi V, Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006;175:2341-4
   PubMed Web of Science ®Google Scholar
• Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009;56:700-6
   Google Scholar
• Khera M, Somogyi GT, Kiss S, Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004;45:987-93
   PubMedGoogle Scholar
• Yoshida M, Masunaga K, Satoji Y, Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci 2008;106:193-8
   PubMedGoogle Scholar
• Schulte-Baukloh H, Zurawski TH, Knispel HH, Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int 2007;100:1075-80
   PubMed Web of Science ®Google Scholar
• Coelho A, Cruz F, Cruz C, Avelino A. Botulinum toxin type A acts on bladder intramural parasympathetic ganglia. An experimental study in the guinea-pig. Eur Urol Suppl 2010;9:59
   Google Scholar
• Datta SN, Roosen A, Pullen A, Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol 2010;184:2578-85
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Di Stasi SM, Stephen RL, Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004;172:240-3
   PubMed Web of Science ®Google Scholar
• Schurch B, de Seze M, Denys P, Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200
   PubMed Web of Science ®Google Scholar
• Ehren I, Volz D, Farrelly E, Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007;41:335-40
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-6
   PubMed Web of Science ®Google Scholar
• Brubaker L, Richter HE, Visco A, Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22
   PubMed Web of Science ®Google Scholar
• Flynn MK, Amundsen CL, Perevich M, Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009;181:2608-15
   PubMed Web of Science ®Google Scholar
• Ghei M, Maraj BH, Miller R, Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005;174:1873-7
   PubMed Web of Science ®Google Scholar
• Popat R, Apostolidis A, Kalsi V, A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-8
   PubMed Web of Science ®Google Scholar
• Kennelly MJ, Kang J. Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cord Inj Rehabil 2003;8:46-53
   Google Scholar
• Bagi P, Biering-Sorensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 2004;38:495-8
   PubMed Web of Science ®Google Scholar
• Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004;63:868-72
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Mearini E, Di Stasi SM, New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nephrol 2004;56:79-87
   Google Scholar
• Kessler TM, Danuser H, Schumacher M, Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24:231-6
   PubMed Web of Science ®Google Scholar
• Smith CP, Nishiguchi J, O'Leary M, Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005;65:37-41
   PubMed Web of Science ®Google Scholar
• Klaphajone J, Kitisomprayoonkul W, Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 2005;86:2114-18
   PubMedGoogle Scholar
• Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653-9
   PubMed Web of Science ®Google Scholar
• Hajebrahimi S, Altaweel W, Cadoret J, Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 2005;12:2543-6
   PubMedGoogle Scholar
• Schulte-Baukloh H, Schobert J, Stolze T, Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: An objective and subjective analysis. Neurourol Urodyn 2006;25:110-15
   PubMed Web of Science ®Google Scholar
• Kalsi V, Apostolidis A, Popat R, Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006;49:528-35
   PubMed Web of Science ®Google Scholar
• Kalsi V, Popat RB, Apostolidis A, Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519-27
   PubMed Web of Science ®Google Scholar
• Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006;67:232-6
   PubMed Web of Science ®Google Scholar
• Ruffion A, Capelle O, Paparel P, What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006;97:1030-4
   PubMed Web of Science ®Google Scholar
• Karsenty G, Reitz A, Lindemann G, Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68:1193-7
   PubMed Web of Science ®Google Scholar
• Kalsi V, Gonzales G, Popat R, Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452-7
   PubMed Web of Science ®Google Scholar
• Reitz A, Denys P, Fermanian C, Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007;52:1729-35
   PubMed Web of Science ®Google Scholar
• Chenet A, Perrouin-Verbe B, Le Normand L, Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity. Ann Readapt Med Phys 2007;50:651-60
   PubMedGoogle Scholar
• Kalsi V, Apostolidis A, Gonzales G, Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 2008;54:181-7
   PubMed Web of Science ®Google Scholar
• Game X, Castel-Lacanal E, Bentaleb Y, Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613-18
   PubMed Web of Science ®Google Scholar
• Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 2009;104:1246-50
   PubMed Web of Science ®Google Scholar
• Grosse J, Kramer G, Jakse G. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int 2009;104:651-6
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Rossi A, Mearini E, Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009;182:1453-7
   PubMed Web of Science ®Google Scholar
• Ghalayini IF, Al-Ghazo MA, Elnasser ZA. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity. Int Urol Nephrol 2009;41:805-13
   PubMedGoogle Scholar
• Hori S, Patki P, Attar KH, Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int 2009;104:216-20
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55:705-11
   PubMed Web of Science ®Google Scholar
• Reitz A, Stohrer M, Kramer G, European experience of 200 cases treated with Botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510-5
   PubMed Web of Science ®Google Scholar
• Schmid DM, Sauermann P, Werner M, Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176:177-85
   PubMed Web of Science ®Google Scholar
• Del Popolo G, Filocamo MT, Li Marzi V, Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol 2008;53:1013-20
   PubMed Web of Science ®Google Scholar
• Harper M, Popat R, DasGupta R, A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003;92:325-6
   PubMedGoogle Scholar
• Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-a toxin on patients with severe urge urinary incontinence. J Urol 2004;172:2316-20
   PubMedGoogle Scholar
• Rapp DE, Lucioni A, Katz EE, Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004;63:1071-5
   PubMedGoogle Scholar
• Kalsi V, Apostolidis A, Gonzales G, Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 2008;54:181-7
   Google Scholar
• Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005;96:848-52
   PubMed Web of Science ®Google Scholar
• Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005;66:94-8
   PubMed Web of Science ®Google Scholar
• Lucioni A, Rapp DE, Gong EM, Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 2006;13:3291-5
   PubMedGoogle Scholar
• Lee JC, Yokoyama T, Hwang HJ, Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity. FEMS Immunol Med Microbiol 2007;51:201-11
   PubMedGoogle Scholar
• Ghalayini IF, Al-Ghazo MA. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 2007;26:531-6
   PubMed Web of Science ®Google Scholar
• Karsenty G, Elzayat E, Delapparent T, Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007;177:1011-14
   PubMed Web of Science ®Google Scholar
• Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005;192:1735-40
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Weiss C, Stolze T, Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005;48:984-90
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Weiss C, Stolze T, Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005;66:82-7
   PubMedGoogle Scholar
• Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 2005;19:880-2
   PubMed Web of Science ®Google Scholar
• Jeffery S, Fynes M, Lee F, Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007;100:1302-6
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple CR, Nitti V, Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22
   PubMed Web of Science ®Google Scholar
• Karsenty G, Denys P, Amarenco G, Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275-87
   PubMed Web of Science ®Google Scholar
• Schurch B, Denys P, Kozma CM, Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007;52:850-8
   PubMed Web of Science ®Google Scholar
• Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin A injection. Urology 2008;72:1056-60
   PubMed Web of Science ®Google Scholar
• Stoehrer M, Wolff A, Kramer G, Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int 2009;83:379-85
   PubMedGoogle Scholar
• Anger JT, Weinberg A, Suttorp MJ, Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 2010;183:2258-64
   PubMed Web of Science ®Google Scholar
• Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:424-6
   PubMedGoogle Scholar
• Hirst GR, Watkins AJ, Guerrero K, Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 2007;69:69-73
   PubMedGoogle Scholar
• Khan S, Kessler TM, Apostolidis A, What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol 2009;181:1773-8
   PubMed Web of Science ®Google Scholar
• Sahai A, Dowson C, Khan MS, Dasgupta P. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010;75:552-8
   PubMed Web of Science ®Google Scholar
• Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006;68:993-8
   PubMed Web of Science ®Google Scholar
• Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007;178:1359-63
   PubMed Web of Science ®Google Scholar
• Cohen BL, Rivera R, Barboglio P, Gousse A. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol 2007;177:1006-10
   PubMedGoogle Scholar
• Cohen BL, Barboglio P, Rodriguez D, Gousse AE. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009;28:205-8
   PubMed Web of Science ®Google Scholar
• Petrou SP, Parker AS, Crook JE, Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc 2009;84:702-6
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang CC, Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009;182:786-92
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Michael T, Schobert J, Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002;59:325-8
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003;44:139-43
   PubMedGoogle Scholar
• Riccabona M, Koen M, Schindler M, Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004;171:845-8
   PubMedGoogle Scholar
• Schulte-Baukloh H, Knispel HH, Stolze T, Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005;66:865-70
   PubMedGoogle Scholar
• Kajbafzadeh AM, Moosavi S, Tajik P, Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 2006;68:1091-6
   PubMedGoogle Scholar
• Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 2006;175:1102-5
   PubMedGoogle Scholar
• Akbar M, Abel R, Seyler TM, Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 2007;100:639-45
   PubMedGoogle Scholar
• Neel KF, Soliman S, Salem M, Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder. J Urol 2007;178:2593-7
   PubMedGoogle Scholar
• Kajbafzadeh A, Mahboubi AH, Payabvash S. Concomitant repeated intravesical injections of botulinum toxin-type A and laparoscopic antegrade continence enema; a new solution for an old problem. BJU Int 2009;103:1248-54
   PubMedGoogle Scholar
• Neel KF, Salem M, Soliman S. Total endoscopic management (TEM approach) of children with non-compliant neuropathic bladder: a preliminary report. J Pediatr Urol 2008;4:124-6
   PubMedGoogle Scholar
• Do Ngoc Thahn C, Audry G, Forin V. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. J Pediatr Urol 2009;5:430-6
   Google Scholar
• Hoebeke P, De Caestecker K, Vande Walle J, The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 2006;176:328-31
   PubMed Web of Science ®Google Scholar
• Marte A, Borrelli M, Sabatino MD, Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur J Pediatr Surg 2010;20:153-7
   PubMed Web of Science ®Google Scholar
• Kajbafzadeh AM, Nikfarjam L, Mahboubi AH, Dianat S. Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia. Urology 2010;76:233-7
   PubMedGoogle Scholar
• Wyndaele JJ, vanDromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40:599-600
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Le Gall N, Dasgupta P. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008;71:455-9
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Bigalke H, Miller K, Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008;15:407-15
   PubMed Web of Science ®Google Scholar
• Cohen BL, Caruso DJ, Kanagarajah P, Gousse AE. Predictors of response to intradetrusor botulinum toxin-a injections in patients with idiopathic overactive bladder. Adv Urol 2009:328364
   Google Scholar
• White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin A for refractory overactive bladder in the elderly population. J Urol 2008;180:2522-6
   PubMedGoogle Scholar
• Comperat E, Reitz A, Delcourt A, Histologic features in the urinary bladder wall affected from neurogenic overactivity – a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006;50:1058-64
   PubMedGoogle Scholar
• Apostolidis A, Jacques TS, Freeman A, Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008;53:1245-53
   PubMed Web of Science ®Google Scholar
• Birzele J, Mehnert U, Schurch B. Preseving voiding function and alleviation of overactive bladder symptoms with 100 units of botulinum neurotoxin A in multiple sclerosis patients: a promising therapy? Eur Urol Suppl 2009;8:242
   Google Scholar
• Kessler TM, Khan S, Panicker J, Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009;113:1046-51
   PubMed Web of Science ®Google Scholar
• Wefer B, Ehlken B, Bremer J, Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (Botox®) therapy in Germany. World J Urol 2010;28:385-90
   Google Scholar
• Lamb BW, Patki P, Wood S, 10-year projection for actuarial costs for botulinum toxin injections and clam cystoplasty in patients with neurogenic and idiopathic overactive bladder. Eur Urol Suppl 2010;9:61
   Google Scholar
• Leong RK, De Wachter S, van Kerrebroeck P. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010;84:245-53
   PubMedGoogle Scholar